Jul 5, 2024, 15:03
Andrea Apolo: Phase 1 study of Cabozantinib, Nivolumab, and Ipilimumab for genitourinary tumours
Andrea Apolo, Chief of Bladder Cancer Section Genitourinary Malignancies Branch Center for Cancer Research at NCI, shared on X:
“Cabozantinib/Nivolumab and Cabozantinib/Nivolumab/Ipilimumab have shown promising efficacy and safety in patients with metastatic urothelial carcinoma, metastatic renal cell carcinoma and rare GU tumors in a dose-escalation phase I study.”
Additional information.
Source: Andrea Apolo/X
Jul 8, 2024, 03:35